Clinical efficacy and safety of HAIC combined with lenvatinib and tislelizumab based on FOLFOX regimen in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus
基于FOLFOX方案的HAIC联合仑伐替尼和替雷利珠单抗治疗中晚期肝细胞癌合并门静脉癌栓的临床疗效和安全性研究

摘要

目的 研究并分析基于FOLFOX方案的HAIC联合仑伐替尼和PD1单抗治疗中晚期肝细胞癌合并门静脉癌栓的临床疗效和安全性。方法 以2020年9月1日至2021年11月30日 这一时间段作为研究时段，选取本院接收的56例肝细胞癌合并门静脉癌栓的患者作为本次研究对象，随机分为两组，对照组和实验组分别具有28例患者，其中对照组患者实行仑伐替尼和替雷利珠单抗治疗，实验组则在此前提下进行基于FOLFOX方案的HAIC联合治疗。治疗完成后对比两组患者的临床疗效。结果 实验组患者的临床治疗总有效率高于对照组，数据差异明显具有统计学意义（P<0.05），并且不显著增加并发症发生率。结论 采用基于FOLFOX方案的HAIC联合仑伐替尼和PD1单抗治疗中晚期肝细胞癌合并门静脉癌栓患者具有良好的临床疗效，并且不增加并发症的发生率。

Abstract

Objective: To study and analyze the clinical efficacy and safety of HAIC combined with lenvatinib and PD1 monoclonal antibody based on FOLFOX regimen in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.
Methods Taking the period from September 1, 2020 to November 30, 2021 as the research period, 56 patients with hepatocellular carcinoma combined with portal vein tumor thrombus received in our hospital were selected as the research objects and randomly divided into two groups There were 28 patients in the control group and the experimental group, respectively. The patients in the control group were treated with lenvatinib and tislelizumab, and the experimental group was treated with HAIC combined therapy based on the FOLFOX regimen under this premise. After treatment, the clinical efficacy of the two groups of patients was compared.
Results The total effective rate of clinical treatment in the experimental group was higher than that in the control group, and the difference was statistically significant (P<0.05), and the incidence of complications was not significantly increased.
Conclusion   The FOLFOX-based regimen of HAIC combined with lenvatinib and PD1 monoclonal antibody has good clinical efficacy in the treatment of patients with advanced hepatocellular carcinoma complicated with portal vein tumor thrombus, and does not increase the incidence of complications.